Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Eli Lilly has announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase I clinical testing as a potential non-opioid treatment for chronic pain conditions.

Lilly gets its hands on non-opioid pain asset

Under the terms of the agreement, Lilly will pay Centrexion an upfront payment of $47.5 million and Centrexion may be eligible for up to $575 million in potential development and regulatory milestones. If CNTX-0290 is successfully commercialized, Centrexion would be eligible for up to $375 million in potential sales milestones and tiered royalties ranging from the high-single to low-double digits. Lilly and Centrexion may also elect at a later date to co-promote CNTX-0290 in the US.

"Lilly is committed to developing new medicines for people struggling with chronic pain," said Mark Mintun, vice president of pain and neurodegeneration research at Lilly. "We are pleased to license this early-phase molecule from Centrexion, and look forward to developing it further as a potential non-opioid treatment option for multiple pain conditions."

"This collaboration marks an important step for Centrexion in the progress of its pipeline and demonstrates our ability to identify promising early stage assets working at new targets for chronic pain and efficiently take them through to development," said Jeffrey B. Kindler, chief executive officer of Centrexion. "Lilly's robust pain management portfolio and successful track record developing and commercializing novel therapies make them an ideal company to advance CNTX-0290. Importantly, this agreement aims to efficiently deliver an innovative new treatment to patients that can address the significant unmet medical need of chronic pain."

Read More

Related news

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more 
rfxcel Awarded ISO 9001:2015 Certification

rfxcel Awarded ISO 9001:2015 Certification

14 Aug 2019

rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Using mobile phones to fight Alzheimer’s disease

Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Researchers develop 3D printed ingestible pill

Researchers develop 3D printed ingestible pill

4 Aug 2019

Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.

Read more 
Needle free: Erase wrinkles without injection

Needle free: Erase wrinkles without injection

15 Jul 2019

Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more